|
| | ORIGINAL ARTICLE | | | | | Year : 2008 | Volume : 26 | Issue : 4 | Page : 333-337 | | | Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii
R Srinivasa Rao1, R Uma Karthika1, SP Singh1, P Shashikala2, R Kanungo2, S Jayachandran1, K Prashanth1
1 Department of Biotechnology, School of Life Sciences, Pondicherry University, R. Venkataraman Nagar, Kalapet, Puducherry - 605 014, India
2 Department of Clinical Microbiology, Pondicherry Institute of Medical Sciences, Puducherry - 605 014, India
| Date of Submission | 01-Mar-2008 | | Date of Acceptance | 28-May-2008 | Correspondence Address:
K Prashanth
Department of Biotechnology, School of Life Sciences, Pondicherry University, R. Venkataraman Nagar, Kalapet, Puducherry - 605 014
India
  | 12 |
DOI: 10.4103/0255-0857.43566 PMID: 18974485 Purpose: To study the qualitative and quantitative methods for the investigation of biofilm formation and to examine the correlation between biofilm and antibiotic resistance among the clinical isolates of Acinetobacter baumannii . We also verified the association between biofilm and presence of extended spectrum β-lactamases, particularly, bla PER-1 . Methods: A total of 55 isolates were subjected to susceptibility testing by disc diffusion method for 13 clinically relevant antibiotics. Screening for biofilm production was done by both qualitative and quantitative methods through tube and microtitre plate assay respectively. The presence of bla PER-1 was checked by PCR. Results: A. baumannii isolates showed very high resistance (>75%) to imipenem, cephotaxime, amikacin and ciprofloxacin. Only cefoperazone, netillin and norfloxacin were found to be effective agents. Results of microtitre and tube methods were concordant with 34 isolates (62%) showing biofilm formation. Resistance to four antibiotics such as amikacin (82% vs. 17.6%, P <0.001), cephotaxime (88% vs. 11%, P P <0.001), ciprofloxacin (70% vs. 29%, P =0.005) and aztreonam (38% vs. 11%, P =0.039) was comparatively higher among biofilm producers than non-biofilm producers. Microtitre assay additionally detected 14 weakly adherent isolates. Only 11 isolates had bla PER-1 gene and among these two were strong biofilm producers, while remaining were weakly adherent isolates. Conclusion: Microtitre plate method was found to be a more sensitive method for biofilm detection. This study demonstrates a high propensity among the clinical isolates of A. baumannii to form biofilm and a significant association of biofilms with multiple drug resistance. Presence of bla PER-1 appears to be more critical for cell adherence than for biofilm formation.
Keywords: A. baumannii; biofilm; bla PER-1 ; MDR
How to cite this article:
Rao R S, Karthika R U, Singh S P, Shashikala P, Kanungo R, Jayachandran S, Prashanth K. Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii. Indian J Med Microbiol 2008;26:333-7 |
How to cite this URL:
Rao R S, Karthika R U, Singh S P, Shashikala P, Kanungo R, Jayachandran S, Prashanth K. Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii. Indian J Med Microbiol [serial online] 2008 [cited 2014 Mar 11];26:333-7. Available from: http://www.ijmm.org/text.asp?2008/26/4/333/43566 |
Acinetobacter baumannii has emerged as an important and problematic human pathogen as it is the causative agent of several types of infections including pneumonia, meningitis, septicaemia, and urinary tract infections. It ranked second after Pseudomonas aeruginosa among the nosocomial, aerobic, non-fermentative, gram negative bacilli pathogens. [1] Furthermore, this organism frequently causes infections associated with medical devices, e.g., vascular catheters, cerebrospinal fluid shunts, Foley catheters etc. [2],[3],[4] A. baumannii has emerged recently as a major cause of hospital acquired infections because of the extent of its antimicrobial resistance and its propensity to cause large, often multi-facility nosocomial outbreaks. [2],[3],[4] Mortality in patients suffering from A. baumannii infections can be as high as 75%. [2] Infections due to A. baumannii often prove difficult to treat due to high level of resistance to multiple antibiotics as a result of both intrinsic and acquired mechanisms. [5],[6] The potential ability of A. baumannii to form biofilms might also explain its outstanding antibiotic resistance, survival properties and increased virulence. [2],[6],[7] Indeed one of the recent studies showed a positive correlation between the biofilm formation and presence of extended spectrum of β - lactamase (ESBL) bla PER-1 among the A. baumannii isolates. [8] A contrary observation was also noticed in yet another study. [9]
Biofilm formation is a well-known pathogenic mechanism in device related infections in hospitals. [10] Moreover, the environmental survival of some nosocomial pathogens may be facilitated by biofilm formation on abiotic surfaces. Little is known concerning the biofilm formation and its mechanisms in A. baumannii . [7],[11],[12],[13]
Therefore, the present study was undertaken on clinical isolates of A. baumannii to determine the frequency of biofilm formation by different methods and correlate biofilm formation with development of multiple antibiotic resistance and ESBL production. Furthermore, we also verified existence of any association between biofilm formation and presence of ESBL particularly, bla PER-1 .
| ~ Materials and Methods | |  |
Bacterial isolates
A total of 55 isolates of A. baumannii in the study were obtained from Pondicherry Institute of Medical Sciences Hospital (PIMS), Puducherry, India, from various clinical specimens like endotracheal aspirates, cerebrospinal fluid, wound swabs, urine and blood culture specimens from patients admitted in ICUs and acute medical care units during January to April 2007. All the isolates were characterised to the species level using phenotypic tests as described elsewhere. [14],[15] Antimicrobial susceptibility testing was performed for 13 different therapeutically relevant antibiotics by Kirby Bauer disk diffusion method according to norms of Clinical Laboratory Standards Institute (CSLI). [16] Antibiotics tested included amikacin (10 µg), aztreonam (30 µg), ceftazidime (30 µg), cefotaxime (30 µg), ceftriaxone (30 µg), ciprofloxacin (5 µg), cefepime (30 µg) cefoperazone (30 µg), cefazolin (5 µg), imipenem (10 µg), netillin (30 µg), norfloxacin (30 µg) and ofloxacin (30 µg) which were obtained from Hi-Media, Mumbai.
Biofilm production
Biofilm formation was checked only for 51 isolates out of 55 isolates. Biofilm production was estimated qualitatively for all the isolates by tube method as described previously by Christensen et al . [17] Biofilm production was determined quantitatively using modified microtitre plate method described elsewhere. [18] A. baumannii ATCC 19606 strain was taken as the positive control and a non-biofilm forming bacteria ( Escherichia More Details coli strain) as a negative control.
All tests were carried out in triplicates and the results were averaged. In the present study, only strongly adherent ones were taken as biofilm positive while weakly adherent ones were taken as negative for biofilm production.
PCR for bla PER-1
All isolates of A. baumannii were tested for the presence of bla PER-1 gene by PCR. Detection of bla PER-1 gene was performed using primers that were described in previous investigation. [8] The PCR reaction mixture (10μL) contained 1μL of reaction buffer (containing 1.5 mM of MgCl2), 50 μM of each deoxyribonucleoside triphosphate, 50 pmol of each PER-1 primer, 0.5U of Taq polymerase (Bangalore Genei) and 30 ng of DNA template. PCR amplifications were performed using thermocycler (Eppendorf, Germany) with following cycling conditions: (i) initial denaturation step of 5 minutes at 94°C, (ii) 30 cycles of PCR, with each cycle consisting of 30 seconds at 94°C, 30 seconds at 55°C, and 30 seconds at 72°C, and (iii) a final extension step of 5 minutes at 72°C. PCR end products were analysed on 1.2% agarose gel, stained with ethidium bromide. Statistical analysis was performed wherein categorical variables were compared using the Chi-square test (or Fisher's exact test, if required). Differences were significant if the p value associated with the test was < 0.05.
| ~ Results | | |
Qualitative tube method of biofilm screening showed 34 isolates (62%) positive for biofilm production. Most of the isolates showed thick blue ring at the liquid-air interface. Some of the isolates showing positive results in tube method are shown in [Figure 1]. In the quantitative assay for the biofilm production, the isolates were classified as strongly biofilm producing (strongly adherent), weakly adherent isolates and non-biofilm producers (non-adherent). Quantitative microtitre assay for biofilm formation was strongly positive in 34 isolates (62%) while the remaining isolates were either weakly adherent (14) or non-biofilm producers (3). Fourteen weakly adherent isolates were considered as negative or non-biofilm producers. Both the methods for biofilm detection thus showed similar results. Isolates screened for biofilm formation by microtitre plate assay method are shown in [Figure 2].
The overall percentage of resistance observed among all the A. baumannii isolates including biofilm producers and biofilm non-producers for 13 antibiotics tested, is given in [Table 1]. A. baumannii isolates showed 100% resistance to imipenem, 89% resistance to cephotaxime, 80% to amikacin and 73% to ciprofloxacin. Cefoperazone and norfloxacin were found to be more effective against most of the isolates. Almost all the multiple antibiotic resistant isolates tested positive for biofilm formation.
The multi-drug resistance patterns of the biofilm producing A. baumannii isolates is shown in [Table 2]. All the biofilm forming isolates showed maximum resistance to imipenem (100%), followed by cephotaxime (88%), amikacin (82%) and ciprofloxacin (70%). Both biofilm producers and non-producers were completely resistant to imipenem. However, resistance to other three antibiotics such as amikacin (82% vs. 17.6%, P <0.001), cephotaxime (88% vs 11%, P <0.001), and ciprofloxacin (70% vs 29%, P =0.005) was comparatively higher among biofilm producers than non-biofilm producers [Table 1]. Resistance among biofilm producers to aztreonam was also high (38% vs 11%, P =0.039) when compared with non-biofilm producers. Least resistance (5%) was noticed only for cefoperazone. Majority of clinical isolates of A. baumannii , which were isolated from wound infection (44%) showed strong positive results for the biofilm formation. Thirty percent of biofilm producers were from nosocomial pneumonia patients where endotracheal aspirate was the clinical specimen. The third highest number of biofilm producers (12%) were isolated from urinary tract infection. In all remaining sites, the isolation of biofilm producers was less than 6%.
The maximum multiple resistance among the isolates was noticed for antimicrobial agents such as imipenem, cephotaxime, amikacin, cefazolin and ciprofloxacin. Isolates predominantly showed five unique drug combination profiles [Table 2]. Highest number of isolates (14) showed the profile Ce, Cf, Cz, I, followed by Ak, Ce, Cz, Of, I which had 12 isolates. The resistograms of 13 isolates obtained from different clinical specimens displayed definite patterns [Table 3]. Isolates collected from patients' endotracheal aspirate showed three distinct profiles of resistance namely 1A, 1B, 1C in which a group of nine isolates were resistant to three sets of the same antibiotics. Similarly the isolates from wound infection showed two sets (1C, 2) of unique resistance profiles and two of the isolates from urine showed one unique profile.
Presence of bla PER-1 gene was confirmed by detection of DNA fragment of the size 900bp. Eleven isolates showed the presence of bla PER-1 gene, four from respiratory infection, five from wound infection and one each from traumatic meningitis and urinary tract infection [Figure 3]. The amplicon size was ~875bp in three of the isolates. Among the 11 bla PER-1 positive isolates, only two showed strong adherence while the remaining nine were weakly adherent. All the 11 bla PER-1 positive isolates were multi-drug resistant and were also resistant to all the β - lactam antibiotics tested. Two biofilm positive isolates (strain ID No. 14 and 28) that were bla PER-1 positive were found to be multi-drug resistant having resistant patterns Ak, Ce, Cf, Ci, Cpm, Cz, I, Nt, Of and Ak, Ce, Cf, I respectively.
| ~ Discussion | | |
A. baumannii infections present a global medical challenge. They are opportunistic pathogens and are particularly successful at colonizing and persisting in the hospital environment. They are able to resist desiccation and survive on inanimate surfaces for years. [2],[3],[4],[6] Interest in this organism has been growing rapidly because of the emergence of multi-drug-resistant strains, some of which are pan-resistant to antimicrobial agents. [2],[6],[19] It is also among the most common causes of device-related nosocomial infection that results when the organism is able to resist physical and chemical disinfection, often by forming a biofilm. Biofilm formation is thought to be a key pathogenic feature, especially in relation to intravascular line infections and ventilator associated pneumonia. Generally, two properties are often associated with biofilm producing bacteria, namely, the increased synthesis of exopolysaccharide (EPS) and the development of antibiotic resistance. [20] One can assume that increased production of EPS in A. baumannii is likely to create a protective environment leading to difficulty in antibiotic penetration leading to development of resistance. In addition, there appears to be some differences in the cellular physiology of cells within the biofilm that also results in increased drug resistance. [21] Thus infections due to bacteria that form biofilms are a tenacious clinical problem. Only, few reports have described the ability of clinical isolates of A. baumannii to attach and form biofilms on glass surfaces. [7],[8],[12] We chose to investigate biofilm formation by clinical isolates of A. baumannii and multiple drug resistance among them and tried to correlate them in order to understand how this pathogen persists in the hospital environment and causes outbreaks.
In the present study, both the qualitative and quantitative method showed 34 isolates (62%) as strong biofilm producers. Fourteen isolates, which were weakly adherent, were additionally picked up by the quantitative microtitre assay asserting its sensitiveness. However, as adherence alone may not complete the cycle of process of biofilm formation and there might be many other mechanisms that could explain adherence, [20],[21] we categorised isolates that were weakly adherent as biofilm negative. One of the recent studies [9] had 63% biofilm positive isolates among the 92 studied, which was comparable with our results. Biofilm forming isolates were also less frequently resistant to imipenem and ciprofloxacin in that study [9] while our results showed positive association in biofilm positivity and multiple drug resistance particularly to certain antibiotics. Compared to non-biofilm producers our study also detected significantly higher resistance to cephotaxime, amikacin, ciprofloxacin and aztreonam among biofilm producers. Non-biofilm producers showed increased resistance only for netillin and ofloxacin.
Interestingly, it was observed that 44% of isolates (15) among the biofilm positive isolates were isolated from wound infections. These isolates were strongly positive for biofilm. Additionally, 30% of biofilm producers were from pneumonia patients. This indicates that in wound and respiratory infections biofilm may contribute to antibiotic resistance. Appropriate antibiotic selection for the treatment of such biofilm associated infections is extremely important. Carbapenems have been the antibiotics of choice for treatment of infections caused by this organism, but resistance to carbapenems is becoming common, and very few therapeutic options remain. In our study, all the isolates were imipenem resistant which is the most common antibiotic prescribed in this hospital. In addition, high percentage of resistance was also witnessed to cephotaxime, amikacin and ciprofloxacin. The potential ability of A. baumannii to form biofilms could explain this outstanding antibiotic resistance. [7] In concurrence with the other studies [9],[22] we noted that 62% of our isolates that were strong biofilm producers, also showed nearly complete resistance to all the antibiotics tested. Nevertheless, a few of the strong biofilm forming isolates were sensitive to some of the antibacterial agents namely cefoperazone, norfloxacin and netillin. This could be due to the ability of some of these antibiotics to penetrate the biofilms, thereby inhibiting the bacterial growth.
In our study, among the 34 biofilm positive isolates, the resistograms of 13 isolates isolated from different clinical sources like endotracheal aspirate, wound, urine, CSF and blood, displayed distinct patterns (antibiotypes 1A, 1B, 1C, 2, 3). Such antibiotypes imply that the same isolate is being isolated from different patients over a period of time and it also emphasises on persistence and dissemination of A. baumannii in hospital environment. Here, gaining the ability to form biofilm could be a good strategy to enhance the survival and persistence under stressed conditions, e.g. during host invasion or following antibiotic treatment. As a consequence of biofilm development it is said that the ability of Acinetobacter to transfer genes horizontally might also enhance within these micro communities facilitating the spread of antibiotic resistance. [8] Thus, A. baumannii isolates capable of forming biofilm might be selected under antibiotic pressure, or conversely, A. baumannii might acquire resistance to multiple drugs within biofilm communities. In either case, it appears that the high colonising capacity of A. baumannii , combined with its resistance to multiple drugs, contributes to the organism's survival and further dissemination in the hospital setting. By acquiring various kinds of resistance mechanisms, biofilm phenotype of A. baumannii has developed into one of the most difficult hospital pathogen to control and treat. Nevertheless, not much is known about the mechanism that triggers the development of biofilm in A. baumannii .
Lee et al , [8] have previously reported that there is a strong relationship between biofilm formation and the production of PER-1 β-lactamases. However in our study, only two strong biofilm (strongly adherent) forming isolates were positive for PER-1 β-lactamases. Interestingly, rest of the PER-1 β-lactamase positive isolates (n=9) were weakly adherent or produced negligible biofilm. This observation is in concurrence with the study of Sechi et al , [13] wherein no correlation existed between PER-1 β-lactamase positive isolates and biofilm producers. Nonetheless, these bla PER-1 positive isolates were strongly associated with cell adhesion. [13] From the above observations, we believe that presence of bla PER-1 is more critical for cell adhesion than for biofilm formation.
Overall, the present study demonstrated a high propensity among the clinical isolates of A. baumannii to form biofilm and there was a significant association of biofilms with multiple drug resistance. bla PER-1 presence is likely to facilitate cell adherence. Biofilm production in A. baumannii might promote increased colonization and persistence leading to higher rates of device related infections. A greater understanding of the nature of biofilms and intercellular communications within the biofilm and also their role in serious infections of A. baumannii will help in development of new and more effective treatment for Acinetobacter infections.
| ~ References | | |
| 1. | Jeong SH, Bae IK, Park KO, An YJ, Sohn SG, Jang SJ, et al . Outbreaks of imipenem-resistant Acinetobacter baumannii producing carbapenemases in Korea. J Microbiol 2006;44:423-31.  [PUBMED] [FULLTEXT] | | 2. | Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: Multidrug resistant Acinetobacter baumannii . Nat Rev Microbiol 2007;5:939-51. [PUBMED] [FULLTEXT] | | 3. | Prashanth K, Badrinath S. Epidemiological investigation of nosocomial Acinetobacter infections using AP-PCR and Pulse field gel electrophoresis. Indian J Med Res 2005;122:408-18. [PUBMED] [FULLTEXT] | | 4. | Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: An emerging challenge to clinicians. Ann Pharmacother 2004;38:1449-59. [PUBMED] [FULLTEXT] | | 5. | Van Looveren M, Goossens H; ARPAC Steering Group. Antibacterial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004;10:684-704. | | 6. | Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005;18:306-13. [PUBMED] [FULLTEXT] | | 7. | Tomaras AP, Dorsey CW, Edelmann RE, Actis LA. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii : Involvement of a novel chaperone-usher pili assembly system. Microbiology 2003;149:3473-84. [PUBMED] [FULLTEXT] | | 8. | Lee HW, Koh YM, Kim J, Lee JC, Lee YC, Seol SY, et al . Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces. Clin Microbiol Infect 2008;14:49-54. [PUBMED] [FULLTEXT] | | 9. | Rodr?guez-Ban˜o J, Marti S, Soto S, Fernandez-Cuenca F, Cisneros JM, Pachon J, et al . Biofilm formation in Acinetobacter baumannii : Associated features and clinical implications. Clin Microbiol Infect 2008;14:276-8. | | 10. | Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358:135-8. [PUBMED] [FULLTEXT] | | 11. | Vidal R, Dominguez M, Urrutia H, Bello H, Gonzalez G, Garcia A, et al . Biofilm formation by Acinetobacter baumannii . Microbios 1996;86:49-58. [PUBMED] | | 12. | Vidal R, Dominguez M, Urrutia H, Bello H, Garcia A, Gonzalez G, et al . Effect of imipenem and sulbactam on sessile cells of Acinetobacter baumannii growing in biofilm. Microbios 1997;91:79-87. [PUBMED] | | 13. | Sechi LA, Karadenizli A, Deriu A, Zanetti S, Kolayli F, Balikci E, et al . PER-1 type beta-lactamase production in Acinetobacter baumannii is related to cell adhesion. Med Sci Monit 2004;10: BR180-4. [PUBMED] [FULLTEXT] | | 14. | Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol 1991;29:277-82. [PUBMED] [FULLTEXT] | | 15. | Kenchappa P, Sreenivasmurthy B. Simplified panel of assimilation tests for identification of Acinetobacter species. Indian J Pathol Microbiol 2003;46:700-6. | | 16. | Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 16th informational supplement, M100-S16. Wayne, PA: CLSI, 2006. | | 17. | Christensen GD, Simpson WA, Bisno AL, Beachey EH. Adherence of slime-producing strains of Staphylococcus epidermidis to smooth surfaces. Infect Immun 1982;37:318-26. [PUBMED] [FULLTEXT] | | 18. | Stepanovic S, Vukovic D, Davic I, Savic B, Svabic-Vlahovic M. A Modified microtiter-plate test for quantification of Staphylococcal biofilm formation. J Microbiol Methods 2000;40:175-9. | | 19. | Prashanth K, Badrinath S. In vitro susceptibility pattern of clinically significant Acinetobacter species to commonly used cephalosporins, quinolones, and aminoglysocides. Indian J Med Microbiol 2004;22:97-103. [PUBMED]  | | 20. | Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science 1999;284:1318-22. [PUBMED] [FULLTEXT] | | 21. | Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother 2001;45:999-1007. [PUBMED] [FULLTEXT] | | 22. | Siroy A, Cosette P, Seyer D, Lemaξtre-Guillier C, Vallenet D, Van Dorsselaer A, et al . Global comparison of the membrane subproteomes between a multidrugresistant Acinetobacter baumannii strain and a reference strain. J Proteome Res 2006;5:3385-98. |
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2], [Table 3]
| This article has been cited by | | 1 | Assessment of Biofilm Formation and Resistance to Imipenem and Ciprofloxacin among Clinical isolates of Acinetobacter baumannii in Tehran | | | Ahya Abdi-Ali,Saghar Hendiani,Parisa Mohammadi,Sara Gharavi | | Jundishapur Journal of Microbiology. 2014; 7(1) | | [Pubmed] | | | 2 | Investigating the Link Between Imipenem Resistance and Biofilm Formation by Pseudomonas aeruginosa | | | Hadeel K. Musafer,Sherry L. Kuchma,Amanda A. Naimie,Joseph D. Schwartzman,Harith J. Fahad AL-Mathkhury,George A. O’Toole | | Microbial Ecology. 2014; | | [Pubmed] | | | 3 | Use of a stainless steel washer platform to study Acinetobacter baumannii adhesion and biofilm formation on abiotic surfaces | | | S. J. Orsinger-Jacobsen,S. S. Patel,E. M. Vellozzi,P. Gialanella,L. Nimrichter,K. Miranda,L. R. Martinez | | Microbiology. 2013; 159(Pt_12): 2594 | | [Pubmed] | | | 4 | Proteomic insights into Acinetobacter baumannii drug resistance and pathogenesis | | | Long, Q. and Huang, C. and Liao, P. and Xie, J. | | Critical Reviews in Eukaryotic Gene Expression. 2013; 23(3): 227-235 | | [Pubmed] | | | 5 | Association of biofilm formation with antimicrobial resistance among the Acinetobacter species in a tertiary care hospital in Bangladesh | | | Nahar, A. and Anwar, S. and Miah, M.R.A. | | Journal of Medicine (Bangladesh). 2013; 14(1): 28-32 | | [Pubmed] | | | 6 | Acinetobacter baumannii: Human infections, factors contributing to pathogenesis and animal models | | | McConnell, M.J. and Actis, L. and Pachón, J. | | FEMS Microbiology Reviews. 2013; 37(2): 130-155 | | [Pubmed] | | | 7 | Biofilm formation by clinical isolates and the implications in chronic infections | | | Sanchez Jr, C.J. and Mende, K. and Beckius, M.L. and Akers, K.S. and Romano, D.R. and Wenke, J.C. and Murray, C.K. | | BMC Infectious Diseases. 2013; 13(1) | | [Pubmed] | | | 8 | Antibacterial and antibiofilm effects of iron chelators against Prevotella intermedia | | | J.-H. Moon,C. Kim,H.-S. Lee,S.-W. Kim,J.-Y. Lee | | Journal of Medical Microbiology. 2013; 62(Pt_9): 1307 | | [Pubmed] | | | 9 | Imipenem resistance and biofilm production in Acinetobacter | | | Anu Madanan Sunu Kumari,Abhisek Routray,Deepti Yadav,Radha Madhavan | | Drug Invention Today. 2013; 5(3): 256 | | [Pubmed] | | | 10 | Biofilm formation by clinical isolates and the implications in chronic infections | | | Carlos J Sanchez,Katrin Mende,Miriam L Beckius,Kevin S Akers,Desiree R Romano,Joseph C Wenke,Clinton K Murray | | BMC Infectious Diseases. 2013; 13(1): 47 | | [Pubmed] | | | 11 | Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models | | | Michael J. McConnell,Luis Actis,Jerónimo Pachón | | FEMS Microbiology Reviews. 2012; : n/a | | [Pubmed] | | | 12 | Characterization of bacterial etiologic agents of biofilm formation in medical devices in critical care setup | | | Revdiwala, S. and Rajdev, B.M. and Mulla, S. | | Critical Care Research and Practice. 2012; 2012(945805) | | [Pubmed] | | | 13 | Molecular characterization and antimicrobial susceptibility study of Acinetobacter baumannii clinical isolates from middle east, African and Indian patients | | | Chaudhary, M. and Payasi, A. | | Journal of Proteomics and Bioinformatics. 2012; 5(11): 265-269 | | [Pubmed] | | | 14 | Comparative study assessing the effect of tigecycline and moxifloxacin in prevention of Acinetobacter baumannii biofilm | | | Ibrahim, N.H. and Somily, A.M. and Bassyouni, R.H. and El-Aabedien, A.Z. | | Life Science Journal. 2012; 9(3): 1016-1024 | | [Pubmed] | | | 15 | Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces | | | Espinal, P. and MartÃ, S. and Vila, J. | | Journal of Hospital Infection. 2012; 80(1): 56-60 | | [Pubmed] | | | 16 | Detection of certain virulence attributes and antimicrobial resistance pattern among clinical isolates of acinetobacter baumannii | | | Prakasam, G. and Geethapriya, S. and Jayakeerthana, K.H. and Ramesh, S. | | International Journal of Pharma and Bio Sciences. 2011; 2(3): 501-507 | | [Pubmed] | | | 17 | Proteomic and functional analyses reveal a unique lifestyle for acinetobacter baumannii biofilms and a key role for histidine metabolism | | | Cabral, M.P. and Soares, N.C. and Aranda, J. and Parreira, J.R. and Rumbo, C. and Poza, M. and Valle, J. and Calamia, V. and Lasa, I. and Bou, G. | | Journal of Proteome Research. 2011; 10(8): 3399-3417 | | [Pubmed] | | | 18 | Assessment of biofilm formation in device-associated clinical bacterial isolates in a tertiary level hospital | | | Mulla, S.A. and Revdiwala, S. | | Indian Journal of Pathology and Microbiology. 2011; 54(3): 561-564 | | [Pubmed] | | | 19 | Emergence of tigecycline & colistin resistant Acinetobacter baumanii in patients with complicated urinary tract infections in north India | | | Taneja, N. and Singh, G. and Singh, M. and Sharma, M. | | Indian Journal of Medical Research. 2011; 133(6): 681-684 | | [Pubmed] | | | 20 | Insignificant difference seen on biofilm production among indwelling medical device associated bacterial isolates | | | Mulla, S. and Revdiwala, S. | | Journal of Pharmaceutical Negative Results. 2011; 2(1): 20-23 | | [Pubmed] | | | 21 | Seagrass as a potential source of natural antioxidant and anti-inflammatory agents | | | N. Yuvaraj, P. Kanmani, R. Satishkumar, A. Paari, V. Pattukumar, V. Arul | | Pharmaceutical Biology. 2011; : 1 | | [VIEW] | | | 22 | Proteomic and Functional Analyses Reveal a Unique Lifestyle for <i>Acinetobacter baumannii</i> Biofilms and a Key Role for Histidine Metabolism | | | Maria P. Cabral, Nelson C. Soares, Jesús Aranda, José R. Parreira, Carlos Rumbo, Margarita Poza, Jaione Valle, Valentina Calamia, Íñigo Lasa, Germán Bou | | Journal of Proteome Research. 2011; 10(8): 3399 | | [VIEW] | | | 23 | Acinetobacter baumannii biofilms: Variations among strains and correlations with other cell properties | | | Christin N. McQueary, Luis A. Actis | | The Journal of Microbiology. 2011; 49(2): 243 | | [VIEW] | | | 24 | Acinetobacter baumannii biofilms: Variations among strains and correlations with other cell properties | | | McQueary, C.N., Actis, L.A. | | Journal of Microbiology. 2011; 49(2): 243-250 | | [Pubmed] | | | 25 | Biofilms: A challenge to medical science | | | Bose, S., Ghosh, A.K. | | Journal of Clinical and Diagnostic Research. 2011; 5(1): 127-130 | | [Pubmed] | | | 26 | Fulminating septicemia due to persistent pan-resistant community-acquired metallo - Lactamase (IMP-1)-positive Acinetobacter baumannii | | | Telang, N.V., Satpute, M.G., Dhakephalkar, P.K., Niphadkar, K.B., Joshi, S.G. | | Indian Journal of Pathology and Microbiology. 2011; 54(1): 180-182 | | [Pubmed] | | | 27 | Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection | | | Dai, N., Li, D.-Z., Chen, J.-C., Chen, Y.-S., Geng, R., Hu, Y.-H., Yang, J.-P., (...), Gao, Z.-C. | | Chinese Medical Journal. 2010; 123(18): 2571-2575 | | [Pubmed] | | | 28 | In silico analysis of antibody triggering biofilm associated protein in Acinetobacter baumannii | | | Mohammad Reza Rahbar, Iraj Rasooli, Seyed Latif Mousavi Gargari, Jafar Amani, Yaser Fattahian | | Journal of Theoretical Biology. 2010; 266(2): 275 | | [VIEW] | | | 29 | In silico analysis of antibody triggering biofilm associated protein in Acinetobacter baumannii | | | Rahbar, M.R., Rasooli, I., Mousavi Gargari, S.L., Amani, J., Fattahian, Y. | | Journal of Theoretical Biology. 2010; 266(2): 275-290 | | [Pubmed] | | | 30 | Regulation of Acinetobacter baumannii biofilm formation | | | Gaddy, J.A., Actis, L.A. | | Future Microbiology. 2009; 4(3): 273-278 | | [Pubmed] | | | 31 | Corynebacterium diphtheriae as an emerging pathogen in nephrostomy catheter-related infection: Evaluation of traits associated with bacterial virulence | | | Gomes, D.L.R., Martins, C.A.S., Faria, L.M.D., Santos, L.S., Santos, C.S., Sabbadini, P.S., Souza, M.C., (...), Mattos-Guaraldi, A.L. | | Journal of Medical Microbiology. 2009; 58(11): 1419-1427 | | [Pubmed] | | | 32 | Activity of tigecycline on planktonic and sessile cells of Acinetobacter baumannii [Tigesiklinin Acinetobacter baumannii planktonik ve biyofilm hücrelerine etkisi] | | | Can, F. and Kaya, M. and Bayindir, F.B. and Uncu, H. and Demirbilek, M. and Yazici, A.C. | | Mikrobiyoloji Bulteni. 2009; 43(4): 587-595 | | [Pubmed] | | | 33 | Activity of tigecycline on planktonic and sessile cells of Acinetobacter baumannii | [Tigesiklinin Acinetobacter baumannii planktonik ve biyofilm hücrelerine etkisi] | | | Can, F., Kaya, M., Bayindir, F.B., Uncu, H., Demirbilek, M., Yazici, A.C. | | Mikrobiyoloji Bulteni. 2009; 43(4): 587-595 | | [Pubmed] | | | 34 | Corynebacterium diphtheriae as an emerging pathogen in nephrostomy catheter-related infection: evaluation of traits associated with bacterial virulence | | | D. L. R. Gomes,C. A. S. Martins,L. M. D. Faria,L. S. Santos,C. S. Santos,P. S. Sabbadini,M. C. Souza,G. B. Alves,A. C. P. Rosa,P. E. Nagao,G. A. Pereira,R. Hirata,A. L. Mattos-Guaraldi | | Journal of Medical Microbiology. 2009; 58(11): 1419 | | [Pubmed] | |
| | |   | | | | |
